Lon­za inks deal with first cus­tomer at re­cent­ly-ex­pand­ed Chi­na man­u­fac­tur­ing site

Just one week af­ter Swiss drug­mak­er Lon­za an­nounced that an ex­pan­sion of its API de­vel­op­ment and man­u­fac­tur­ing labs at a Nan­sha, Chi­na, site has been com­plet­ed, the first part­ner to ben­e­fit from that up­grade has been an­nounced.

Oas­mia Phar­ma­ceu­ti­cals has inked a deal with Lon­za to man­u­fac­ture its ovar­i­an can­cer drug can­di­date Cantrix­il at the Nan­sha site. The agree­ment cov­ers de­liv­er­ing drug sub­stance through Phase II clin­i­cal tri­als and is set to kick off this month. Lon­za will pro­vide kilo­gram-scale syn­the­sis, pu­rifi­ca­tion, sta­bil­i­ty test­ing of Cantrix­il and cGMP batch­es of drug sub­stance for clin­i­cal sup­ply, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER